Expert Interview
Discussing available treatment options for CLL patients, and how BTK degraders, particularly ones in development by BeOne (BGB-16673) and Nurix Therapeutics (bexobrutideg), could fit into the treatment algorithm
Ticker(s): NRIX, BeOne MedicinesInstitution: UCI Irvine
- Hematologist and Oncologist, and Associate Professor — Division of Hematology-Oncology, Department of Medicine, UCI School of Medicine.
- Currently manages 200 patients with CLL annually
- Specializes in chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL), which has been her research focus for more than a decade as a principal investigator of numerous clinical trials of novel agents that have improved the care of these patients.
How are you currently treating CLL patients?
Added By: wilson_adminWhere would BTK degraders slot into the treatment algorithm?
Added By: wilson_adminAre you going to start using Jaypirca in earlier lines?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
